N/A
N=230
Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)
Non Small-cell Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT01662635 ↗Enrolled (actual)
230
Serious AEs
—
Results posted
Nov 2014
Primary outcome: Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Primary completion
- Sep 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY FISH, IHC, RT-qPCR Comparison |
18; 15; 5; 182; 48; 43 | < 0.05 sig |
Summary
Because ALK-positive lung cancer constitutes less than 5% of all lung cancers, it is critically important to select those patients who are more likely to have the ALK mutation. Clinical characteristics of patients with mutations in the target gene should also be known, so that the incidence of a given target mutation is established in a specific population. There is not incidence known in Mexican population, but it is believed it is greater.
Eligibility Criteria
Inclusion Criteria
- The only inclusion criterion was the availability of tissue for biomarker studies.
Exclusion Criteria
- Disease Progression
Data sourced from ClinicalTrials.gov (NCT01662635). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.